Market Cap
$834.3M
LXRX
LEXICON PHARMACEUTICALS, INC.
$1.82 ▲ +0.00%
Prev close $1.82Market cap$834.3M
ConsensusBuy
12-mo target$4.55 (+149.8%)
▲ Bullish
Analyst conviction 7/10
High Impact Filing (7/10)14 New Institutional Positions14 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on LXRX right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (73%)
Inst. Holders
50 funds
Inst. Value
$290.0M
Inst. Activity
14 buys / 14 sells
Insider Activity
$297.8K buy / $0.00 sell
Insider Net $
$297.8K
Social Sentiment
50° Neutral
SEC Reports
9
Press Releases
3
Price chart 30d -19.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Aug 6, 2026 SEC Short Volume: LXRX — 68.2% short (0.5M / 0.7M)
Short: 477,764 | Exempt: 0 | TRF Vol: 700,183 | Short Ratio: 68.2% | Off-exchange volume (dark pool
Lexicon Pharmaceuticals reported Q2 2026 revenue of $0.7M, down 97.6% from $28.9M a year ago due to the absence of a $27
PRESS-RELEASE — Impact 5/10
Lexicon Pharmaceuticals reported Q2 2026 total revenue of $0.7M, a sharp decline from $28.9M in Q2 2025 which included a
8-K — Impact 5/10
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
17,348,741 shares ($41.6M)
Jun 30, 2026 Inst.
Jun 12, 2026 SEC GEODE CAPITAL MANAGEMENT, LLC — ADD
6,244,372 shares ($15.0M)
A mixed institutional cluster emerged in LXRX during Q3 2024: four asset managers (led by Legal & General Group doubling
INST-CLUSTER — Impact 5/10
Jun 3, 2026 Insider
DEBBANE RAYMOND acquired via exercise 89,312 shares
Director
Jun 3, 2026 Insider
BARKER SAM L acquired via exercise 89,312 shares
Director
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
73% rate it Buy or better · 11 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 28, 2026 | Cantor Fitzgerald | INITIATE | Overweight | 49% |
| May 11, 2026 | Citigroup | MAINTAIN | Buy | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Aug 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Jul 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Jun 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| May 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Apr 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Mar 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Feb 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% |
Price targets
Where 6 covering analysts think LXRX trades over the next 12 months.
$4.55 +149.8% upside Strong Buy
Current$1.82 Low$2.00 Median$4.55 High$8.00 6 analysts
$2.00$8.00
Analyst rating Buy· 1.8/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 1 bullish, 2 bearish, 0 mixed, 6 neutral · avg impact 4.3/10.Plus 3 press releases.
NEUTRALPRESS-RELEASE5/10
Lexicon Pharmaceuticals reported Q2 2026 revenue of $0.7M, down 97.6% from $28.9M a year ago due to
Aug 6, 2026
NEUTRAL8-K5/10
Lexicon Pharmaceuticals reported Q2 2026 total revenue of $0.7M, a sharp decline from $28.9M in Q2 2
Aug 6, 2026
BEARISHINST-CLUSTER5/10
A mixed institutional cluster emerged in LXRX during Q3 2024: four asset managers (led by Legal & Ge
Jun 12, 2026
NEUTRALINST-CLUSTER2/10
A weak institutional cluster in LXRX shows 4 buyers (Schwab, Two Sigma, BofA, Morgan Stanley) adding
Jun 11, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
short_volume
Short Volume: LXRX — 68.2% short (0.5M / 0.7M)
Short: 477,764 | Exempt: 0 | TRF Vol: 700,183 | Short Ratio: 68.2% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: LXRX — 77.8% short (1.2M / 1.5M)
Short: 1,186,668 | Exempt: 0 | TRF Vol: 1,525,636 | Short Ratio: 77.8% | Off-exchange volume (dark pool + OTC)
Sep 22, 2026
short_volume
Short Volume: LXRX — 59.8% short (0.8M / 1.3M)
Short: 764,025 | Exempt: 4,761 | TRF Vol: 1,277,503 | Short Ratio: 59.8% | Off-exchange volume (dark pool + OTC)
Sep 21, 2026
short_volume
Short Volume: LXRX — 72.2% short (0.4M / 0.6M)
Short: 414,931 | Exempt: 301 | TRF Vol: 574,571 | Short Ratio: 72.2% | Off-exchange volume (dark pool + OTC)
Sep 18, 2026
short_volume
Short Volume: LXRX — 62.6% short (0.4M / 0.6M)
Short: 391,325 | Exempt: 100 | TRF Vol: 624,981 | Short Ratio: 62.6% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.05 | $-0.06–$-0.04 | -32.3% | +11.2% | 0↑ 1↓ | $0.0B | 3 |
| Next Q | $-0.04 | $-0.04–$-0.03 | 9.8% | +23.1% | 2↑ 0↓ | $0.0B | 3 |
| Current FY | $-0.17 | $-0.18–$-0.15 | -18.8% | -4.8% | 0↑ 2↓ | $0.0B | 3 |
| Next FY | $-0.19 | $-0.27–$-0.11 | -14.6% | +7.6% | 0↑ 1↓ | $0.0B | 4 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.053 | — |
| 7d ago | $-0.060 | +0.007 |
| 30d ago | $-0.060 | +0.007 |
| 60d ago | $-0.060 | +0.007 |
| 90d ago | $-0.060 | +0.007 |
Institutional ownership
Which big funds own LXRX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $290.0M total value (120,824,048 shares) as of 2026-Q2. Top holders: FMR, BlackRock,, VANGUARD.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 51,782,045 | $124.3M | 42.9% | — |
| BlackRock, Inc. | 17,348,741 | $41.6M | 14.4% | DOUBLED +422.2% |
| VANGUARD CAPITAL MANAGEMENT LLC | 9,901,208 | $23.8M | 8.2% | — |
| Point72 Asset Management, L.P. | 8,251,325 | $19.8M | 6.8% | DOUBLED +2651.4% |
| GEODE CAPITAL MANAGEMENT, LLC | 6,244,372 | $15.0M | 5.2% | ADD +97.0% |
| STATE STREET CORP | 4,917,769 | $11.8M | 4.1% | DOUBLED +410.1% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2,357,749 | $5.7M | 2.0% | DOUBLED +331.3% |
| NORTHERN TRUST CORP | 1,968,619 | $4.7M | 1.6% | DOUBLED +298.0% |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,956,775 | $4.7M | 1.6% | ADD +49.2% |
| VANGUARD FIDUCIARY TRUST CO | 1,634,571 | $3.9M | 1.4% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | DOUBLED | 3,322,219 | 17,348,741 | +422.2% | $41.6M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 3,169,111 | 6,244,372 | +97.0% | $15.0M |
| STATE STREET CORP | DOUBLED | 964,038 | 4,917,769 | +410.1% | $11.8M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | DOUBLED | 546,600 | 2,357,749 | +331.3% | $5.7M |
| NORTHERN TRUST CORP | DOUBLED | 494,666 | 1,968,619 | +298.0% | $4.7M |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 1,311,298 | 1,956,775 | +49.2% | $4.7M |
| CITADEL ADVISORS LLC | ADD | 1,094,901 | 1,601,182 | +46.2% | $3.8M |
| MILLENNIUM MANAGEMENT LLC | NEAR_EXIT | 4,944,731 | 1,134,229 | -77.1% | $2.7M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,600,500 | 1,127,000 | -29.6% | $2.7M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | TRIM | 2,121,164 | 696,776 | -67.2% | $1.7M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
16 insiders, 50 transactions. Net $297.8K — $297.8K bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | DEBBANE RAYMOND | Director | EXERCISE | 89,312 | — | — |
| Jun 3, 2026 | BARKER SAM L | Director | EXERCISE | 89,312 | — | — |
| Jun 3, 2026 | Amouyal Philippe | Director | EXERCISE | 89,312 | — | — |
| Jun 3, 2026 | Cheung Ivan | Director | EXERCISE | 89,312 | — | — |
| Jun 3, 2026 | Sullivan Diane E. | Director | EXERCISE | 89,312 | — | — |
| Jun 3, 2026 | SOBECKI CHRISTOPHER J | Director | EXERCISE | 89,312 | — | — |
| Jun 3, 2026 | Swain Judith L | Director | EXERCISE | 89,312 | — | — |
| May 1, 2026 | DEBBANE RAYMOND | Director | AWARD | 35,714 | — | — |
| May 1, 2026 | DEBBANE RAYMOND | Director | AWARD | 43,478 | — | — |
| May 1, 2026 | Swain Judith L | Director | AWARD | 35,714 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for LXRX.
Shares short
28,793,507
Settlement Sep 15, 2026
Change vs prior
-2.4%
Semi-monthly cycle
Days to cover
13.4
At avg daily volume
Of shares outstanding
≈6.5%
Estimate — not % of float
All LXRX filing & press-release reports (12)
- PRESS-RELEASE reportAug 6, 2026
- 8-K reportAug 6, 2026
- INST-CLUSTER reportJun 12, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 6, 2026
- 8-K reportApr 30, 2026
- PRESS-RELEASE reportApr 30, 2026
- PRESS-RELEASE reportMar 24, 2026
- PRESS-RELEASE reportMar 23, 2026
- DEFA14A reportMar 16, 2026
- 8-K reportMar 5, 2026
- PRESS-RELEASE reportMar 5, 2026